Case report: Treatment of rocuronium-induced anaphylactic shock with vasopressin

Canadian Journal of Anesthesia

Volumn 55, Issue 7, 2008, Pages 437-440

  Meng, Li ^a,b   Williams, E Lynne ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b C205 PUH ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ARGIPRESSIN; CHLORPHENIRAMINE; CISATRACURIUM; DEXAMETHASONE; FAMOTIDINE; FENTANYL; LIDOCAINE; PHENYLEPHRINE; PROPOFOL; REMIFENTANIL; ROCURONIUM; SEVOFLURANE;

ADOLESCENT; ALLERGY TEST; ANAPHYLACTIC SHOCK; ANESTHESIA INDUCTION; ARTICLE; BLOOD PRESSURE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; ENDOTRACHEAL INTUBATION; ERYTHEMA; FEMALE; FLUID THERAPY; GENERAL ANESTHESIA; HEMODYNAMICS; HUMAN; HYPOPHYSIS TUMOR; HYPOTENSION; PRIORITY JOURNAL; RESUSCITATION; SIDE EFFECT; SINUS TACHYCARDIA; SKIN TEST; TRANSSPHENOIDAL HYPOPHYSECTOMY; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 47149116894     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03016310     Document Type: Article

References (25)

1. Heier T, Guttormsen AB. Anaphylactic reactions during induction of anaesthesia using rocuronium for muscle relaxation: a report including 3 cases. Acta Anaesthesiol Scand 2000: 44: 775-81.
2. Berg CM, Heier T, Wilhelmsen V, Florvaag E. Rocuronium and cisatracurium-positive skin tests in non-allergic volunteers: determination of drug concentration threshold using a dilution titration technique. Acta Anaesthesiol Scand 2003: 47: 576-82.
3. Bhananker SM, O'Donnell JT, Salemi JR, Bishop MJ. The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: an analysis of food and drug administration reporting of adverse events. Anesth Analg 2005; 101: 819-22.
4. Naguib M, Magboul MM. Adverse effects of neuromuscular blockers and their antagonists. Drug Saf 1998: 18: 99-116.
5. Hepner DL, Castells MC. Anaphylaxis during the perioperative period. Anesth Analg 2003; 97: 1381-95.
6. Birnbaum J, Porri F, Pradal M, Charpin D, Vervloet D. Allergy during anaesthesia. Clin Exp Allergy 1994: 24: 915-21.
7. Mettes PM, Laxenaire MC, Alla F; Groupe d'Etudes des Réactions Anaphylactoïds Peranesthésiques. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999-2000. Anesthesiology 2003; 99: 536-15.
8. Guttormsen AB. Allergic reactions during anaesthesia - increased attention to the problem in Denmark and Norway. Acta Anaesthesiol Scand 2001: 45: 1189-90.
9. Levy JH, Yegin A. Anaphylaxis. What is monitored to make a diagnosis? How is therapy monitored? Anesthesiol Clin North America 2001; 19: 705-15.
10. Mertes PM, Laxenaire MC, Lienhar A, et al. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J Investig Allergol Clin Immunol 2005; 15: 91-101.
11. Oliver H, Schafer E. On the physiological action of extracts of the pituitary body and certain other glandular organs. J Physiol 1895; 18: 277-9.
12. Du Vigeaud V, Gash DT, Katsoyaniss PG. A synthetic preparation possessing biological properties associated with arginine-vasopressin. J Am Chem Soc 1954; 76: 4751-2.
13. ECC Committee, Subcommittees and Task Forces of the American Heart Association. 2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112(24 Suppl): IV-1-203.
14. International Liaison Committee on Resuscitation. 2005 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Circulation 2005; 112: III-1-III-136.
15. Jochberger S, Wenzel V, Dunser MW. Arginine vasopressin as a rescue vasopressor agent in the operating room. Curr Opin Anaesthesiol 2005; 18: 396-404.
16. Schummer W, Schummer C, Whippermann J, Fuchs J. Anaphylactic shock: is vasopressin the drug of choice? Anesthesiology 2004; 101: 1025-7.
17. Williams SR, Denault AY, Pellerin M, Martineau R. Vasopressin for treatment of shock following aprotinin administration. Can J Anesth 2004; 51: 169-72.
18. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Int Arch Allergy Immunol 2004; 134: 260-1.
19. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA 3rd. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodila tory septic shock. Crit Care Med 2001; 29: 487-93.
20. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47: 699-703; discussion 703-5.
21. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001; 120: 989-1002.
22. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-73.
23. Ericsson BF. Effect of vasopressin on the distribution of cardiac output and organ blood flow in the anesthetized dog. Acta Chir Scand 1971; 137: 729-38.
24. Dewachter P, Raeth-Fries I, Jouan-Hureaux V, et al. A comparison of epinephrine only, arginine vasopressin only, and epinephrine followed by arginine vasopressin on the survival rate in a rat model of anaphylactic shock. Anesthesiology 2007; 106: 977-83.
25. Hiruta A, Mitsuhata H, Hiruta M, et al. Vasopressin may be useful in the treatment of systemic anaphylaxis in rabbits. Shock 2005; 24: 264-9.